Fungtional Labs

Fungtional Labs: Integrated Supply Chain for Mushroom Cultivators in North America


Fungtional Labs is a leading provider of cultivation supplies and food-grade functional mushrooms in North America. The company’s vertically integrated business model provides robust differentiation over its peers. From cultivation and extraction to testing and end-product sales and distribution, the model ensures multiple revenue streams for Fungtional Labs.

Fungtional Labs’ cultivation supplies based on its proprietary all-in-one growing media include sterilized media, spawn genetics, all-in-one grow bags, pellets and masters mix. The company’s long-term goal is to develop IP around functional and psychedelic mushroom extracts.

Revenue Streams​Revenue Streams

Some of the company's revenue streams include selling food-grade gourmet and functional mushrooms in North America and bulk substrates, growing medias, genetics, growing equipment, which has generated significant demand among cultivators and commercial growers.

Company Highlights

  • Fungtional Labs is a vertically integrated business model that provides products from cultivation to end-product consumer sales and distribution. This provides an advantage over peers by eliminating intermediaries.
  • Fungtional Labs is a supplier of cultivation and genetic products for mushroom cultivators in North America, leveraging its proprietary all-in-one growing media. The company’s products include sterilized media, spawn genetics and all-in-one grow bags.
  • The company’s proprietary organic master mix growing media is in high demand among cultivators, providing higher yield at lower costs.
  • The company plans to implement its business model over three phases – Phase 1 will focus on providing mycological supplies and producing functional mushroom varieties; 2) Phase 2 will focus on processing finished products, as well as focus on submitting a licensed dealer application to manufacture psilocybin-enhanced products; and 3) Phase 3 will involve B2B white labelling services, as well as, operating as a licensed dealer in the psychedelics market.
  • The company’s mycological division, which supplies all-natural growth formulas and extraction methods, stands to benefit from sector tailwinds and a large addressable market. The global food fungi market is expected to grow to $69 billion by 2024, while the medicinal mushroom extract market is expected to reach $18 billion by 2024.
  • The company’s long-term goal is to develop IP around functional and psychedelic mushroom extracts. The company anticipates to provide different delivery systems to very evolving psychedelic market. The psychedelic market presents a large opportunity for the company given that the market is projected to grow at a CAGR of 16.3 percent by 2027.

This Fungtional Labs profile is part of a paid investor education campaign.*

Click here to connect with Fungtional Labs to receive an Investor Presentation

The Conversation (0)
Mushrooms on cutting board with knife.

Functional Mushrooms: A Market Overview

Functional mushrooms are experiencing a surge in popularity as their health and wellness benefits become increasingly well-known. Driven by multiple intersecting trends, this popularity is directly reflected in the market performance and outlook for functional mushroom products.

Gaining a deeper understanding of the market data and the progression of the functional mushroom industry can provide investors valuable insights into the opportunities in this emerging market.

Also known as adaptogenic or medicinal mushrooms, functional mushrooms are a subset of fungi valued for their potential health benefits. Whereas ordinary mushrooms provide good nutritional content, functional mushrooms contain a range of bioactive compounds, including beta-glucans, polysaccharides, triterpenoids and antioxidants. Owing to their therapeutic effects, functional mushrooms have a long history in herbal and traditional medicine.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharma ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy portfolio

  • In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks 1

  • Endothelin A (ETA) receptor activation contributes to elevated proteinuria in IgAN 2-5 ; atrasentan is a potent, selective ETA receptor antagonist with potential to reduce persistent proteinuria and preserve kidney function for a broad patient population 1

  • IgAN is a heterogeneous, progressive, rare kidney disease with a need for effective, targeted therapies 6,7 ; up to 30% of patients with persistent proteinuria (≥1 g/day) progress to kidney failure within 10 years 8

  • Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression

Novartis today presented results from a pre-specified interim analysis of the Phase III ALIGN study of atrasentan, an investigational oral selective endothelin A (ETA) receptor antagonist, in patients with IgA nephropathy (IgAN) 1 . Patients treated with atrasentan, in addition to supportive care (maximally tolerated and stable dose of a renin-angiotensin system [RAS] inhibitor), achieved a 36.1% (p

Proteinuria reduction is a recognized surrogate marker correlating with delaying progression to kidney failure and has been used as an endpoint in IgAN clinical trials to support accelerated regulatory approvals 10 . US FDA submission for atrasentan in IgAN is on track for the first half of 2024.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Novartis presents latest Phase III Fabhalta® data in C3 glomerulopathy showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo

  • Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo 1 ; additional 6-month open-label data to be presented at a future medical meeting 2,3

  • Fabhalta showed a favorable safety profile with no new safety signals 1

  • C3G, an ultra-rare kidney disease caused by alternative complement pathway overactivation, progresses to kidney failure in ∼50% of patients within 10 years 4-7 ; currently there are no treatments approved for C3G 7-9

  • Fabhalta, an oral Factor B inhibitor of the alternative complement pathway, selectively targets the underlying cause of C3G 1 ; late-stage development program ongoing across several other rare diseases 10-13

Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta ® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress 1 . Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care 1 . In many kidney diseases, proteinuria reduction is an increasingly recognized surrogate marker correlating with delaying progression to kidney failure 14,15 .

Fabhalta is an oral Factor B inhibitor of the alternative complement pathway being investigated in adult patients with C3 glomerulopathy (C3G) 1-3 . Regulatory submissions, including to the FDA and EMA, for the adult C3G indication are planned for the second half of 2024.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Logistics management concept.

The Business Case for Vertical Integration

Business models and go-to-market strategies are important elements of any investment decision.

In that regard, a vertically integrated business model offers several unique advantages over traditional business models, including enhanced resilience and access to multiple revenue streams across the value chain.

Understanding vertically integrated business models can help investors evaluate investment opportunities, particularly in new and emerging market segments.

Keep reading...Show less
Medicine capsule showing its active ingredients.

Pharma Stocks: 5 Biggest Companies in 2024

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less

Latest Press Releases

Related News

×